Mechanistic research outpaces standardized clinical protocols, yielding heterogeneous real-world outcomes.

Researchers are rapidly learning how psychedelics work in the brain, but that knowledge is moving faster than the ability to turn it into consistent, safe treatment guidelines for clinics. In the real world — especially with ketamine, which is already legally prescribed — outcomes vary wildly depending on who's giving the treatment and how. This gap between what scientists know and what clinicians reliably do is getting wider, not smaller.

Today's basic-science signals advance understanding while real-world ketamine cohorts show uncontrolled variability. The translation gap widens, not narrows.